Prospective Validation of American Thyroid Association (ATA) Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study
Authors' conclusion
Our study confirms the favorable initial outcome of microPTC in a large series. We demonstrate that the ATA risk classification is reliable in predicting biochemical and structural persistence in patients with microPTC. Distant metastases, although rare, remain the best predictor of structural persistence at 1-year follow-up. These findings underscore the importance of tailored management strategies based on comprehensive risk stratification, rather than solely on tumor size.
Study context
- Population
- Patients with histologically diagnosed papillary thyroid carcinoma (PTC), consecutively enrolled in the Italian Thyroid Cancer Observatory, with complete pathological, clinical, treatment and 1-year follow-up data
- Participants
- 5,038 patients
- Exposure
- MicroPTC vs macrocarcinoma
- microPTCn = 2,345
- Outcome
- Predictors of biochemical and structural incomplete response in microPTC
- Follow-up
- 1 year after initial treatment
Methodological detailsmulticentre registry, consecutively enrolled, real-world
- Multicentre registry
- Consecutively enrolled
- Real-world
Main finding
As reported in the abstract
Biochemical response in microPTC
5%
Structural incomplete response (SIR) in microPTC
2.3%
Distant metastases at diagnosis as predictor of SIR in microPTC, OR
5.13
95% CI 1.11–23.73P = .04
Observational data: associations, not effects.
Further findings
Baseline risk features of microPTC · diagnosis
- ATA high risk
- 3%
- Distant metastases at diagnosis
- 1%
Predictor of SIR, subgroup treated by total thyroidectomy and RAI · 1 year
- Subgroup n
- 925
- ATA high risk as predictor of SIR, OR
- 5.47 (95% CI 1.42-21.04, P = .01)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →